Solutions

Online Inquiry

Name *

Email *

Phone *

Services Interested *

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

CDX Mouse/Rat Model Development Services

With rich experience in preclinical research in the field of cancer therapy, Alfa Cytology provides one-stop services for cell line xenograft (CDX) mouse/rat model development, helping researchers successfully achieve their research goals.

Introduction to Cell Line Xenograft (CDX) Mouse/Rat Model

The cell line xenograft (CDX) mouse/rat model is a preclinical in vivo model for cancer research, which is constructed by transplanting in vitro cultured human or murine tumor cell lines into immunodeficient mice/rats. These models are used to study the behavior and response of human cancer cells in animal hosts and allow researchers to study tumor growth, metastasis, and response to various treatments. Such models are commonly used to evaluate the efficacy of new cancer therapies and to better understand the mechanisms of tumor growth and response to therapies.

Fig. 1 Schematic diagram of building CDX model and PDX model. Fig.1 Schematic diagram of establishing CDX and PDX models. (Li, Z., et al., 2023)

Features of Cell Line Xenograft (CDX) Mouse/Rat Model

Cell line-derived xenograft (CDX) mouse/rat models are characterized by the following main features:

High tumor formation rate
Short modeling time

Good reproducibility
Low cost

Small differences in individual animal tumor formation

Our Services

Alfa Cytology provides you with CDX models for breast, liver, intestinal, pancreatic, lung, gastric, kidney, prostate, melanoma, bladder, leukemia, ovarian and brain cancers, etc. We also offer customized modeling solutions for specific project needs.

Our Mouse Strains

Nude and BALB/c nude
SCID (Severe combined immunodeficiency)
Severe immunodeficient mice (BRGSF and C-NKG, etc.)

Inoculation Sites

Subcutaneous Inoculation
Orthotopic Inoculation
Intravenous Inoculation
Intraperitoneal Inoculation

Our Rat Strains

RNU (Rowett Nude)
Sprague-Dawley SCID
ZDF (Zucker Diabetic Fatty) Nude

Cell Line Models Available

We offer a wide range of histotypes, including broad tumor models. Here are some examples:

Histotype	Cell Line Models Available
Breast	MCF-7, T-47D, MDA-MB-231, BT-474, ZR-75-1, SK-BR-3, HCC1954, Hs578T, SUM159, MDA-MB-468, etc.
Colon	94, CL-34, COLO 205, DiFi, DLD-1, HCC-2998, HCT 116, HCT-15, HT-29, KM12, KM20L2, LoVo, LS-174T, LS411N, RKO, SW48, SW480, SW620, etc.
Prostate	LNCaP, PC-3, DU145, 22Rv1, VCaP, RWPE-1, LAPC-4, CWR22, NCI-H660, PNT2, etc.
Gastric	3011, FU97, IM95, MKN1, MKN45, N87, NUGC-4, SCH, SNU-5, etc.
Leukemia	ARH-77, CCRF-CEM, EM-2, HEL92.1.7, HL-60, JURKAT, JURL-MK1, K562, Kasumi-1, KCL-22, KG-1, KG-1a, MEC-1, MEG-01, MOLM-13, etc.
Liver	HepG2, Huh7, Hep3B, SNU-387, SNU-423, SNU-449, PLC/PRF/5, SK-HEP-1, Mahlavu, Alexander, etc.
Lung	A549, H1299, H460, H1650, H1975, HCC827, Calu-3, PC-9, NCI-H23, NCI-H522, etc.
Lymphoma	Daudi, DoHH-2, Granta 519, HUT-78, Z-138, KARPAS-299, Mino, Namalwa, OCI-LY7, Raji B, Ramos, etc.
Melanoma	SK-MEL-28, WM35, WM115, M14, HS294T, G361, C32, UACC-62, A2058, A375, CHL-1, COLO 800, HT-144, IGR-1, IGR-37, LOX, UACC-62, etc.
Ovarian	Kuramochi, A2780, AG6000, BG1, IGR0V1, OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8, TOV-21G, CAOV3, SKOV3, COV318, KURAMOCHI, OVSAHO, etc.
Pancreas	PANC-1, MiaPaCa-2, BxPC-3, AsPC-1, Capan-1, CFPAC-1, SW1990, SU.86.86, HPAC, HPAF-II, etc.

Pharmacological Assessment Services

Alfa Cytology also provides a variety of pharmacological assessment tools such as tumor growth curve/body weight curve, hematology (CBC/Diff) analysis, histopathology or tissue sampling (frozen section, paraffin section, HE staining, immunohistochemistry, etc.), biomarker screening, sampling or evaluation, flow and molecular assays, in vivo microdialysis, and in vivo implantable microdevices, which can meet your various needs for drug mechanism of action analysis.

Applications of Our Service

Studies of Tumor Development

CDX models enable detailed analysis of tumor growth inhibition, regression and survival in a controlled in vivo environment.

Drug Response and Pharmacodynamic Studies

These models help to assess tumor response to new drugs, establish dose-response relationships, and help to optimize drug delivery.

In Vivo Drug Screening

CDX models can help high-throughput screening of drug candidates in living organisms, which can identify potential therapeutic compounds based on anti-tumor activity.

Drug Resistance and Mechanism Studies

Elucidating the molecular pathways of resistance to chemotherapy and targeted therapies can help identify biomarkers and potential targets for overcoming resistance.

Why Choose Us?

With our rigorous standardized procedures, we custom develop CDX models with a high degree of accuracy and relevance to aid in the study of human cancer biology, increasing the translational potential of research results.

Consistency

Ensure consistency in tumor implantation and growth, which minimizes variability and improves the reliability of experimental results.

Highly Reproducible

Our model exhibits a uniform tumor growth pattern, helping to accurately assess and compare therapy effects.

Validity

Highly mimics the human tumor microenvironment, including tumor-stroma interactions, angiogenesis, and immune responses.

Genetic Stability

The cell lines used remain genetically stable over multiple passages, ensuring that xenografts retain the characteristics of the original human tumor.

With extensive experience in various cancer models and expertise in tumor and microenvironment, Alfa Cytology is the ideal partner to support your oncology therapeutic research. We provide customers with stock model products, model customization, and joint R&D services to provide you with the best tumor models and look forward to meeting your precise needs. Please let us know your project requirements and we will provide you with a comprehensive service from solution to report. If you have any questions, please feel free to contact us.

Reference

Li, Z., et al.; (2023). Towards an optimal model for gastric cancer peritoneal metastasis: current challenges and future directions. EBioMedicine, 92.

For research use only.